专利检索 ap:("Eli Lilly AND Company") AND inv:"David Andrew COATES" 第 1 页

1.

发明公开
GLUCAGON-LIKE PEPTIDE1 RECEPTOR AGONISTS 审中-公开

公开(公告)号：US20230250092A1

公开(公告)日：2023-08-10

申请号：US18194155

申请日：2023-03-31

申请人： Eli Lilly and Company

发明人： David Andrew COATES , Todd FIELDS , Joseph Daniel HO , Fucheng QU

IPC分类号： C07D405/14 , A61P3/10

CPC分类号： C07D405/14 , A61P3/10 , A61K9/0053

摘要： In an embodiment, the present invention provides a compound of the formula:

or a pharmaceutically acceptable salt thereof, and methods of using this compound for treating type II diabetes mellitus.

2.

发明申请
SSTR4 AGONIST SALTS 有权

公开(公告)号：US20230099116A1

公开(公告)日：2023-03-30

申请号：US17944429

申请日：2022-09-14

申请人： Eli Lilly and Company

发明人： David Andrew COATES , David Michael REMICK

IPC分类号： C07D401/12

摘要： The present invention relates to specific salts of (1S,5R)-(1α,5α,6α)-N-[1,1-dimethyl-2-[(3-methyl-2-pyridyl)oxy]ethyl]-3-azabicyclo[3.1.0]hexane-6-carboxamide, to pharmaceutical compositions comprising said salts, to methods of using said salts to treat physiological disorders, and to intermediates useful in the synthesis of the salts.

3.

发明公开
COCRYSTALLINE FORMS OF FGFR3 INHIBITORS 审中-公开

公开(公告)号：US20240116932A1

公开(公告)日：2024-04-11

申请号：US18462286

申请日：2023-09-06

申请人： Eli Lilly and Company

发明人： David Andrew COATES , Lori Raquel HILDEN , Gislaine KUMINEK , Jeffrey A. Peterson

IPC分类号： C07D471/04 , C07C65/05

CPC分类号： C07D471/04 , C07C65/05 , C07B2200/13

摘要： Provided herein are cocrystalline forms of FGFR3 inhibitors and gallic acid or nicotinamide coformers useful in the treatment and prevention of diseases which can be treated with a FGFR3 inhibitor, including FGFR3-associated diseases and disorders, characterizations and methods of making these cocrystalline forms.

4.

发明申请
SOLID FORMS OF 7-[[(1S)-1-[4-[(1S)-2-CYCLOPROPYL-1-(4-PROP-2-ENOYLPIPERAZIN-1-YL)ETHYL]PHENYL]ETHYL]AMINO]-1-ETHYL-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE 有权

公开(公告)号：US20230061806A1

公开(公告)日：2023-03-02

申请号：US17886863

申请日：2022-08-12

申请人： Eli Lilly and Company

发明人： David Andrew COATES , Yizheng CAO

IPC分类号： C07D498/04

摘要： Solid forms including 7-[[(1S)-1-[4-[(1S)-2-cyclopropyl-1-(4-prop-2-enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4H-pyrimido[4,5-d][1,3]oxazin-2-one and a dihydroxybenzoic acid selected from 2,5-dihydroxybenzoic acid, 2,4-dihydroxybenzoic acid, and 2,3-dihydroxybenzoic acid are provided, as well as pharmaceutical compositions including the solid forms, methods for using the solid forms in treating cancer patients, and methods of making the solid forms.

5.

发明申请
DISUBSTITUTED PYRAZOLE COMPOUNDS 有权

公开(公告)号：US20220017496A1

公开(公告)日：2022-01-20

申请号：US17478080

申请日：2021-09-17

申请人： Eli Lilly and Company

发明人： David Andrew COATES , Timothy Barrett DURHAM , Richard Duane JOHNSTON , Steven Marc MASSEY , Patrick Gianpietro SPINAZZE , Douglas Richard STACK , James Lee TOTH

IPC分类号： C07D403/14 , A61P1/16 , A61P3/10 , A61P13/12 , A61P9/04

摘要： The present invention provides a compound of Formula I. or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.

6.

发明申请
(E)-1-(4-(DIMETHYLAMINO)BUT-2-ENOYL)PYRROLIDIN-3-YL 4-((3-ISOPROPYL-5-METHYLPYRAZOLO[1,5-A]PYRIMIDIN-7-YL)AMINO)PIPERIDINE-1-CARBOXYLATE FOR INHIBITING CDK7 审中-公开

公开(公告)号：US20200017513A1

公开(公告)日：2020-01-16

申请号：US16583661

申请日：2019-09-26

申请人： Eli Lilly and Company

发明人： David Andrew COATES , Carlos MONTERO , Bharvin Kumar Rameschandra PATEL , David Michael REMICK , Yipin YADAV

IPC分类号： C07D487/04 , A61P35/00

摘要： The present invention provides novel CDK7 inhibitors and pharmaceutical compositions thereof: or a pharmaceutically acceptable salt thereof.

7.

发明申请
AMINO PYRIMIDINE SSAO INHIBITORS 审中-公开

公开(公告)号：US20190276436A1

公开(公告)日：2019-09-12

申请号：US16356882

申请日：2019-03-18

申请人： Eli Lilly and Company

发明人： David Andrew COATES , Luo Heng QIN , Yi WEI , Jingye ZHOU

IPC分类号： C07D403/04 , A61P1/16 , A61K31/395 , A61K31/715 , C07D401/04

摘要： The present invention provides compounds of the Formula (I), or a pharmaceutically acceptable salt thereof, where n and RI are defined herein, methods of treating patients for liver disease, and processes for preparing the compounds.

8.

发明申请
A TETRAHYDROPYRROLO[3,4-D][1,3]THIAZINE-DERIVATIVE AS BACE INHIBITOR 有权

公开(公告)号：US20170233410A1

公开(公告)日：2017-08-17

申请号：US15504398

申请日：2015-09-08

申请人： Eli Lilly and Company

发明人： David Andrew COATES , Pablo Garcia LOSADA

IPC分类号： C07D513/04

CPC分类号： C07D513/04 , C07B2200/13

摘要： The present invention provides a compound of Formula I: which is crystalline. The compound of Formula (I) is useful in the treatment of Akzheimer's disease (BACE inhibitor).

9.

发明公开
SSTR4 AGONIST SALTS 审中-公开

公开(公告)号：US20240067628A1

公开(公告)日：2024-02-29

申请号：US18366218

申请日：2023-08-07

申请人： Eli Lilly and Company

发明人： David Andrew COATES , David Michael REMICK

IPC分类号： C07D401/12

CPC分类号： C07D401/12 , C07B2200/13

摘要： The present invention relates to specific salts of (1S,5R)-(1α,5α,6α)-N-[1,1-dimethyl-2-[(3-methyl-2-pyridyl)oxy]ethyl]-3-azabicyclo[3.1.0]hexane-6-carboxamide, to pharmaceutical compositions comprising said salts, to methods of using said salts to treat physiological disorders, and to intermediates useful in the synthesis of the salts.

10.

发明申请
SALTS OF 5,6-DIHYDRO-4H-THIENO[2,3-C]PYRROL-4-ONE COMPOUND AS ERK INHIBITORS 有权

公开(公告)号：US20220153750A1

公开(公告)日：2022-05-19

申请号：US17442285

申请日：2020-03-19

申请人： Eli Lilly and Company

发明人： David Andrew COATES , Sajan JOSEPH , Mark Andrew POLIZZI , David Michael REMICK

IPC分类号： C07D495/04

摘要： The present invention provides novel crystalline salt forms of 6,6-dimethyl-2-{2-[(1-methyl-1H-pyrazol-5-yl)amino]pyrimidin-4-yl}-5-[2-(morpholin-4-yl)ethyl]-5,6-dihydro-4H-thieno[2,3-c]pyrrol-4-one.